Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
114.490USD
-3.830-3.24%
Close 07-31 16:00（ET）Quotes delayed by 15 min
12.38BMarket Cap
249.99P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Corcept Therapeutics Inc is 7.67, ranking 97 out of 155 in the Pharmaceuticals industry. The average price target is 137.50, with a high of 144.90 and a low of 121.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
108.142
Target Price
+16.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Corcept Therapeutics Inc
CORT
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Corcept Therapeutics Inc's expected revenue for the next quarter?
Corcept Therapeutics Inc's expected revenue is 336.49M.
What is Corcept Therapeutics Inc's price target?
Analysts forecast that Corcept Therapeutics Inc's price target is USD 137.50, with the highest forecast at USD 144.90 and the lowest forecast at USD 121.00.
How have Corcept Therapeutics IncCORT's recent earnings per share performed?
The market expectation was USD 0.41, while Corcept Therapeutics IncCORT's earnings per share (EPS) for the previous quarter was USD -0.30. EPS for the next quarter is expected at USD 0.42.
What is the analyst rating for Corcept Therapeutics Inc?
Based on the ratings of Corcept Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.